Evidence map›Paper›PMID 39552126›Full record

ArticleBrain and behavior2024

Behavioral Analyses in Dark Agouti Rats Following Repeated Systemic Treatment With Fingolimod (FTY720).

Marie Jakobs, Lisa Trautmann, Martin Hadamitzky, Julia Bihorac, Lucie Jacquet, Uwe Christians, Björn Schniedewind, Laura Lückemann, Manfred Schedlowski

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain and behavior, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marie JakobsInstitute of Medical Psychology and Behavioral Immunobiology, Center for Translational Neuro-Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen, Essen, Germany.ORCID https://orcid.org/0000-0003-4516-9080
Lisa TrautmannInstitute of Medical Psychology and Behavioral Immunobiology, Center for Translational Neuro-Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen, Essen, Germany.
Martin HadamitzkyInstitute of Medical Psychology and Behavioral Immunobiology, Center for Translational Neuro-Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen, Essen, Germany.
Julia BihoracInstitute of Medical Psychology and Behavioral Immunobiology, Center for Translational Neuro-Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen, Essen, Germany.
Lucie JacquetInstitute of Medical Psychology and Behavioral Immunobiology, Center for Translational Neuro-Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen, Essen, Germany.
Uwe ChristiansiC42 Clinical Research and Development, Department of Anesthesiology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Björn SchniedewindiC42 Clinical Research and Development, Department of Anesthesiology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Laura LückemannInstitute of Medical Psychology and Behavioral Immunobiology, Center for Translational Neuro-Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen, Essen, Germany.
Manfred SchedlowskiInstitute of Medical Psychology and Behavioral Immunobiology, Center for Translational Neuro-Behavioral Sciences (C-TNBS), University Medicine Essen, University Duisburg-Essen, Essen, Germany.

Funding

Deutsche Forschungsgemeinschaft 316803389
6 · The paper itself

Abstract

backgroundStudies in experimental animals revealed that acute and chronic treatment with small-molecule immunosuppressive drugs lead to neurobehavioral alterations in rodents.

methodsAgainst this background, this study investigated behavioral alterations in rats after repeated administration of FTY720, an immunosuppressive drug used for the treatment of multiple sclerosis, employing the open field, elevated plus maze, and dark/light tests.

resultsCompared to controls, repeated FTY720 treatment affected behavior in rats, reflected by a reduction in distance traveled as well as increased time engaged in freezing in the open field and elevated plus maze. Furthermore, the time spent freezing in the elevated plus maze test positively correlated with FTY720 concentrations in the amygdala and insular cortex, two brain regions involved in regulation of emotionality. Since no changes in plasma corticosterone levels were observed, stress effects due to treatment, behavioral testing, or handling can be ruled out.

conclusionThe present findings indicate that treatment with FTY720 did not induce typical anxiety-like behavioral patterns in otherwise healthy rats as seen following treatment with other immunosuppressive drugs. Nevertheless, it remains of great importance to evaluate behavioral effects in clinical practice to shed more light onto possible detrimental side effects emerging during treatment with small-molecule immunosuppressive drugs.

Indexed as

CorticosteroneFingolimod HydrochlorideImmunosuppressive AgentsAmygdalaAnimalsAnxietyBehavior, AnimalCerebral CortexMaleRatsCorticosteroneFingolimod HydrochlorideImmunosuppressive Agentsadverse side effectsanxiety‐like behaviorfingolimod (FTY720)immunosuppressive drugs

Identifiers

PMID39552126
PMCPMC11570679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.